What is Raphael Pharm's earnings per share (EPS)?

Raphael Pharm (RAPH) reported diluted earnings per share of $0.07 for fiscal year 2025. This represents a -12.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Raphael Pharm Financials

RAPH

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE March

This page shows Raphael Pharm (RAPH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Earnings Quality Low Quality

0.16x

For every $1 of reported earnings, Raphael Pharm generates $0.16 in operating cash flow (-$210K OCF vs -$1.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$1.3M

YoY+15.8%

Raphael Pharm reported -$1.3M in net income in fiscal year 2025. This represents an increase of 15.8% from the prior year.

EPS (Diluted)

$0.07

YoY-12.5%

Raphael Pharm earned $0.07 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 12.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

N/A

Dividends Per Share

N/A

Shares Outstanding

20M

YoY+7.9%

5Y CAGR+16.4%

Raphael Pharm had 20M shares outstanding in fiscal year 2025. This represents an increase of 7.9% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$631K

YoY-18.7%

5Y CAGR+6.5%

Raphael Pharm invested $631K in research and development in fiscal year 2025. This represents a decrease of 18.7% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

RAPH Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$631K-18.7%	$776K+36.4%	$569K-51.7%	$1.2M+51.8%	$776K+68.3%	$461K
SG&A Expenses	$614K-16.2%	$733K-3.9%	$763K-64.3%	$2.1M+150.8%	$853K+248.2%	$245K
Operating Income	-$1.2M+17.5%	-$1.5M-13.3%	-$1.3M+59.8%	-$3.3M-103.6%	-$1.6M-130.7%	-$706K
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$1.3M+15.8%	-$1.5M-13.0%	-$1.3M+60.0%	-$3.4M-106.6%	-$1.6M-126.3%	-$718K
EPS (Diluted)	$0.07-12.5%	$0.080.0%	$0.08-65.2%	$0.23+53.3%	$0.15	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$73K-48.2%	$141K+95.8%	$72K	N/A	$162K+575.0%	$24K-93.7%	$379K	N/A
SG&A Expenses	$178K+2.3%	$174K-50.7%	$353K	N/A	$157K-30.2%	$225K+33.9%	$168K	N/A
Operating Income	-$251K+20.3%	-$315K+25.9%	-$425K	N/A	-$319K-28.1%	-$249K+54.5%	-$547K	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$255K+20.8%	-$322K+24.9%	-$429K	N/A	-$326K-31.5%	-$248K+54.9%	-$550K	N/A
EPS (Diluted)	$0.01-50.0%	$0.020.0%	$0.02	N/A	$0.010.0%	$0.01-66.7%	$0.03	N/A

RAPH Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	N/A	$27K-88.7%	$239K-28.2%	$333K-21.1%	$422K+30.7%	$323K
Current Assets	N/A	$25K-89.5%	$237K-28.4%	$331K-21.6%	$422K+30.7%	$323K
Cash & Equivalents	N/A	$19K-91.7%	$230K-20.1%	$288K+88.2%	$153K+61.1%	$95K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	$769K+2846.4%	-$28K-112.3%	$227K-22.8%	$294K-19.7%	$366K
Current Liabilities	N/A	$769K+482.6%	$132K-41.9%	$227K-22.8%	$294K-19.7%	$366K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	N/A	-$742K-377.9%	$267K+151.9%	$106K-17.2%	$128K+397.7%	-$43K
Retained Earnings	N/A	-$8.9M-20.6%	-$7.4M-22.3%	-$6.0M-125.9%	-$2.7M-155.7%	-$1.0M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$7K-76.7%	$30K-67.7%	$93K+244.4%	$27K-47.1%	$51K-60.2%	$128K-63.7%	$353K+47.7%	$239K
Current Assets	$5K-82.1%	$28K-69.2%	$91K+264.0%	$25K-49.0%	$49K-61.1%	$126K-64.0%	$350K+47.7%	$237K
Cash & Equivalents	$3K-85.0%	$20K-60.0%	$50K+163.2%	$19K-52.5%	$40K-66.7%	$120K-58.2%	$287K+24.8%	$230K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.3M+17.9%	$1.1M+30.4%	$827K+7.5%	$769K+15.3%	$667K+59.6%	$418K-8.3%	$456K+1728.6%	-$28K
Current Liabilities	$1.3M+17.9%	$1.1M+30.4%	$827K+7.5%	$769K+15.3%	$667K+59.6%	$418K-8.3%	$456K+245.5%	$132K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$1.3M-20.6%	-$1.0M-42.8%	-$734K+1.1%	-$742K-20.5%	-$616K-112.4%	-$290K-181.6%	-$103K-138.6%	$267K
Retained Earnings	-$9.9M-2.6%	-$9.6M-3.5%	-$9.3M-4.8%	-$8.9M-5.4%	-$8.4M-4.0%	-$8.1M-3.2%	-$7.9M-6.6%	-$7.4M

RAPH Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$210K+60.5%	-$532K+55.8%	-$1.2M-58.5%	-$759K+46.5%	-$1.4M-82.2%	-$779K
Capital Expenditures	N/A	N/A	N/A	$2K	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	-$761K	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	-$2K	N/A	N/A
Financing Cash Flow	$236K-26.5%	$321K-72.0%	$1.1M+27.8%	$896K-39.3%	$1.5M+79.2%	$824K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$17K+43.3%	-$30K+85.6%	-$209K-237.1%	-$62K+22.5%	-$80K+63.3%	-$218K-26.7%	-$172K-95.5%	-$88K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	$1K	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	-$173K	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	-$1K	N/A
Financing Cash Flow	$0	$0-100.0%	$240K+485.4%	$41K	$0-100.0%	$50K-78.3%	$230K+1110.5%	$19K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

RAPH Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	-503.4%+2664.6pp	-3167.9%-1898.4pp	-1269.5%	N/A
Return on Assets	N/A	-5625.9%-5063.6pp	-562.3%+446.1pp	-1008.4%-623.3pp	-385.1%-162.8pp	-222.3%
Current Ratio	N/A	0.03-1.8	1.80+0.3	1.46+0.0	1.44+0.6	0.88
Debt-to-Equity	N/A	-1.04-0.9	-0.10-2.2	2.14-0.2	2.30+10.8	-8.51
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-3642.9%-2569.5pp	-1073.3%-612.0pp	-461.3%	N/A	-639.2%-445.5pp	-193.8%-37.9pp	-155.8%	N/A
Current Ratio	0.00-0.0	0.03-0.1	0.11+0.1	0.03-0.0	0.07-0.2	0.30-0.5	0.77-1.0	1.80
Debt-to-Equity	-1.01+0.0	-1.03+0.1	-1.13-0.1	-1.04+0.0	-1.08+0.4	-1.44+3.0	-4.43-4.3	-0.10
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Delivra Health DHBUF

$3.6M

1933 Inds TGIFF

$3.6M

Weed BUDZ

$2.7M

Lftd Partners Inc LIFD

$3.6M

Rafarma Pharmaceuticals Inc. RAFA

$8.6M

Frequently Asked Questions

Is Raphael Pharm profitable?

No, Raphael Pharm (RAPH) reported a net income of -$1.3M in fiscal year 2025.

What is Raphael Pharm's operating cash flow?

Raphael Pharm (RAPH) generated -$210K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

How much does Raphael Pharm spend on research and development?

Raphael Pharm (RAPH) invested $631K in research and development during fiscal year 2025.

How many shares does Raphael Pharm have outstanding?

Raphael Pharm (RAPH) had 20M shares outstanding as of fiscal year 2025.

Are Raphael Pharm's earnings high quality?

Raphael Pharm (RAPH) has an earnings quality ratio of 0.16x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.